Tech IPOs, public-market debuts, and what each one means for the exit environment.
Figma shares fell as much as 16.5% after Q2 revenue beat estimates at $370M but rising AI infrastructure costs and the departure of two senior executives overshadowed a raised full-year outlook.
Gravity Acquisition Corp continued toward its own listing and Alternus Clean Energy issued $14.28M of preferred stock ahead of a planned uplisting, extending the blank-check filing wave Pulse flagged earlier this week.
The US has produced 217 IPOs in 2026, up 6.9% year over year, and almost none of them are venture-backed technology companies -- which is why the count says nothing useful about exit liquidity.
AMD's Q2 results beat consensus and CEO Lisa Su guided to 80% server revenue growth in the second half, but shares fell after Elon Musk said SpaceX would commit fully to Nvidia chips for its AI infrastructure.
Attovia Therapeutics priced its IPO at $17/share, raising roughly $212.5M, and began trading on Nasdaq today under ATTO -- another test of whether biotech's IPO window is genuinely reopening.
Between August 3 and August 5, three SPACs priced at $10 a unit and four more filed or amended registration statements with the SEC -- the densest run of blank-check activity of the summer.
Uber's Q2 gross bookings of $58B topped estimates, but Q3 guidance for both bookings and EPS came in below consensus, sending shares down about 4%.
Attovia Therapeutics priced 17 million shares at $17 to raise $289M on Nasdaq under the ticker ATTO, the largest operating-company listing of the first week of August.
Uber's Q2 gross bookings beat estimates on World Cup travel demand, but Q3 bookings and earnings guidance came in below Wall Street's forecast, sending shares down more than 4% premarket.
Dara Khosrowshahi pushed back on reports that Uber and Waymo are heading for a breakup, on the same day Uber's stock fell on soft forward guidance and Zoox announced paid robotaxi rides in Las Vegas.
The S&P 500 closed at its first record high in two months and the Stoxx 600 touched an all-time high, both propelled by strong earnings and renewed AI-trade optimism despite this week's capex-driven sell-offs.
D-Wave published Nature research showing a fast, high-fidelity entangling gate for its dual-rail superconducting qubits, with simulations suggesting up to a tenfold cut in logical error rates per correction increment.
Robinhood Ventures Fund II is set to list publicly on August 13 at $25 a share, aiming to raise $200M so retail investors can indirectly back roughly 80 Y Combinator-linked private companies -- while paying Robinhood 2% and 20% carry.
Europe's benchmark index set an all-time high, extending a global equity rally that also carried the S&P 500 and Dow to records this week on strong earnings and easing oil prices.
Roughly 911.5 million SpaceX shares become eligible for sale as insider lockups expire this week, a real supply test for a stock already down nearly half from its June IPO peak.
SoftBank shares surged more than 10% as Asian tech stocks tracked a strong Wall Street rally, with Arm's chip royalty optimism and gains at SK Hynix and Samsung all contributing.
SoftBank jumped nearly 14% and the KOSPI and Nikkei both rose more than 3.6% as Asian tech stocks tracked Wall Street's record-setting AI-fueled session.
Pinterest topped Q2 revenue and EPS estimates, but shares fell more than 8% in after-hours trading after Q3 guidance came in below what investors wanted to see.
Pinterest beat Q2 revenue and user growth estimates, but shares fell 7% after the company guided to Q3 revenue growth decelerating to 13-15% amid intensifying ad competition from Instagram.
SpaceX posted $7.81B in Q2 revenue, beating estimates by 13%, but shares swung after AI infrastructure capex hit $15.83B for the quarter, far above what analysts expected.
Attovia Therapeutics priced its Nasdaq IPO at $17 a share while Latigo Biotherapeutics advances its own S-1, the latest signs that the biotech listing window is filling with genuine clinical-stage pipelines.
Lucid launched an operational reset targeting $1.4B in 2026 cash savings, leaning on its Uber- and Nuro-linked robotaxi program as one of four priorities meant to fix a widening quarterly loss.
Ars Technica examines how much of Tesla's profitability still runs through China, and how quickly domestic Chinese EV makers are taking the share that funds it.
Palantir posted $1.94B in Q2 revenue, raised full-year guidance to roughly $8.15B, and watched its stock climb 29% in a single session as US commercial revenue grew 149% year over year.
Latigo Biotherapeutics set terms for a $272M Nasdaq IPO under ticker LTGO, pricing 16M shares at $16-18 to fund late-stage trials of its non-opioid Nav1.8 pain drug, a rival to Vertex's Journax.
Circle's stock trades well below its post-IPO peak even with USDC's volume growing, and that public multiple is the most direct read available on how the market is now pricing Coinbase's own stablecoin-dependent revenue.
Figure AI at a private $39B valuation and China's Unitree pursuing a Shanghai STAR Market listing represent two very different paths to a robotics IPO -- and neither looks genuinely ready by the disclosure standards Cerebras and SpaceX have just set.
Valar Atomics at a $6B private valuation and OLIX at $3.3B are both explicitly infrastructure bets, not software -- and neither has a clear public comp set yet, which means whoever lists first effectively prices the entire category.
Cerebras went public in May at a $56.43B implied valuation, becoming the market's clearest test case for whether a pure-play AI chip challenger to Nvidia can hold a premium multiple once quarterly numbers replace private-market narrative.
While tech IPOs grab headlines, this week's actual new listings are almost entirely biotech -- a sign the broader IPO window is widening beyond the handful of AI mega-caps everyone's watching.
Anthropic confidentially filed for IPO first, at a $965B valuation on a $47B revenue run rate -- but OpenAI's IPO pipeline is also active, and the two companies are now effectively racing to define what an AI-lab public listing should look like.
SpaceX posts its first-ever quarterly results Tuesday after market close, with Wall Street modeling roughly $6.88B in revenue -- the first real test of the $1.4T valuation the market has been pricing on faith since June.
BlossomHill Therapeutics filed for a $100M Nasdaq IPO under ticker BLSM, adding an oncology-focused biotech with $257M in prior funding to a summer pipeline of clinical-stage listings led by J.P. Morgan, Leerink and Guggenheim.
Clear Street's new pre-IPO platform is opening accredited-investor access to $188B-valued Databricks through an SPV structure -- a preview of how late-stage AI names may get priced before they ever file an S-1.
Nuclear reactor supplier Westinghouse Electric confidentially filed for a US IPO, riding investor enthusiasm for nuclear power as Big Tech's AI datacenter buildout strains the grid.
Latigo Biotherapeutics filed an amended S-1 this week, advancing its Nasdaq IPO to fund a pivotal Phase 3 trial for its non-opioid pain drug ahead of the trial itself starting.
SpaceX's first public earnings report and a roughly $116 billion lockup unlock land the same week the stock sits about 20% below its IPO price -- a live test of how much AI-era enthusiasm public markets will still pay for.
Coinbase renewing its Circle revenue-sharing deal even as trading revenue fell 19% for a third straight quarter shows crypto public companies leaning on stable, subscription-like income to offset volatile trading revenue.
Nscale hiring Goldman Sachs and JPMorgan for a possible late-2026 IPO, on the heels of a $14.6 billion private valuation and a $1.65 billion Anyscale acquisition, is an early look at the neocloud sector's own path toward public markets.
Jersey Mike's opened 9% below its IPO price the same day Reformation traded flat, while Apnimed popped 37.5% days later -- public investors are rewarding unmet-need biotech and discounting mature consumer brands.
With OpenAI and Anthropic both racing toward IPOs targeting valuations near $1 trillion, and OpenAI's own leadership reportedly expecting Anthropic to list first, public-market readiness increasingly hinges on profitability trajectory rather than raw scale.
Unitree's Shanghai IPO, with secondary-market chatter running toward $14.8 billion against a $6.2 billion base, is about to give the humanoid-robotics sector its first transparent public price -- a sharp contrast to Figure's opaque $39 billion private mark.
Elon Musk and a select group of SpaceX insiders remaining locked out of this week's share unlock until mid-2027, while other pre-IPO holders can sell, is a founder-alignment signal other AI-scale IPO candidates may want to copy.
Coinbase revenue fell 19% to $1.22B in a third consecutive quarterly decline, yet the company posted a record 10.3% share of global crypto trading volume -- shrinking revenue and growing market share at the same time.
Reformation and Jersey Mike's both priced and debuted within days of each other with muted first-day performance, a real-time read on risk appetite that every AI-adjacent IPO waiting in the wings should be watching closely.
Unitree set public subscription for August 10 on its Shanghai STAR Market IPO, offering 40.45 million shares, with first-half 2026 revenue guidance implying 35.6-45.4% year-over-year growth.
SpaceX is set to acquire roughly 130,000 acres of marshland in southern Louisiana, a major post-IPO capital deployment that lands the same week as its first public earnings report and lockup unlock.
East West Ave Acquisition Corp pricing a $100 million IPO targeting fintech, digital assets and energy deals is a small but real signal that blank-check issuance -- not just SPAC mergers -- is picking back up in 2026.
The US added foreign-made humanoid and quadruped robots to the FCC's national-security Covered List just days before Unitree's Shanghai IPO, effectively closing off what would otherwise be China's largest addressable robotics market.
Unitree Robotics choosing Shanghai's STAR Market over a US listing for its IPO is a clear example of how US-China tensions are pushing China's most valuable AI and robotics companies to list at home, cutting off ordinary US investors from direct access.
Starting August 6, up to 911.5 million SpaceX shares -- worth roughly $116B -- become eligible for sale in a staggered release, a supply event that dwarfs the stock's current public float.
Robinhood now generates more revenue from prediction markets than from traditional stock trading, a structural shift in its business mix that public-market investors are still working out how to price.
Several of 2026's biotech IPOs have expanded their target raise between initial filing and pricing, a sign the sector's strong average return this year has pulled in enough demand that bankers are re-cutting deal size on the fly.
SpaceX's first public earnings report anchors an unusually dense week of public-market disclosures across space, fintech and crypto, giving investors a rare same-week comparison of how differently AI-era companies are actually monetizing.
Between Agility Robotics' $2.5B SPAC merger and Michael Klein's newest blank-check vehicle, 2026's SPAC revival is being built on capital-intensive robotics and infrastructure, not the last cycle's meme stocks.
Three SPACs priced or announced deals in one week -- Churchill Capital XIII, East West Ave, and Space-Eyes' merger vehicle -- a pickup in blank-check issuance overshadowed by this week's AI mega-rounds.
This week's debuts split the 2026 IPO market sharply: differentiated biotech stories got double-digit pops, while mature, sponsor-backed consumer brands opened flat or down regardless of profitability.
Space-Eyes, a Miami-based AI counter-drone and geospatial intelligence startup, will go public via a SPAC merger with McKinley Acquisition Corp at a $638 million equity value.
Apnimed shares jumped as much as 37.5% in their Nasdaq debut after the Phase 3 biotech priced its upsized IPO at $16 a share, raising $192 million to fund what could become the first FDA-approved pill for obstructive sleep apnea.
East West Ave Acquisition Corp priced a $100 million IPO of 10 million units at $10 each, targeting fintech, digital assets and energy deal opportunities as blank-check listings continue picking up in 2026.
